Medication Description: Doxorubicin Hydrochloride (Doxorubicini hydrochloridum)
DOXORUBICINE HYDROCHLORIDE (Doxorubicini hydrochloridum).
Antitumor antibiotic anthracycline series. The chemical structure is close to rubomycin (see). It differs only in that in position 14 it contains, instead of the acetyl group COCH3, oxyacetyl COCH 2 OH, i.e. may be considered as oxyrubomycin.
Synonyms: Adriablastin, Adriamycin, Axidoxo, Blastocin, Doxol, Doxorubifer, Rastocin, Adriamicin, Adriblastin, Aksidoxo, Doxolem, Doxorubicin, Doxorubiferum, Farmiblastina, Hydroxydaunomycin, Rastocin.
Red crystalline powder or porous mass. Moderately soluble in water, insoluble in alcohol.
Doxorubicin has a high antitumor and anti-leukemic activity. The mechanism of action is close to rubomycin, has the ability to intercalate the DNA of cells. It has a depressing effect on blood formation. It has immunosuppressive activity.
Doxorubicin is used in breast cancer, soft tissue sarcoma, osteogenic sarcoma, Ewing tumor, lung cancer, lymphosarcoma, ovarian cancer, squamous cell carcinomas of various localization, bladder cancer, Wilms tumor, thyroid cancer, acute leukemia, lymphogranuloma leukemia, lymphogranulomatosis, and leukemia.
Enter only intravenously. Assign according to one of the following schemes: a) 30 mg per 1 m 2 of body surface daily for 3 days; the intervals between courses are 4 weeks; b) 60 mg / m 2 1 time every 3 weeks; c) on Zomg / m 2 1 time per week (1st, 8th and 15th days of the course). Courses repeated at intervals of 3 weeks.
The total dose of doxorubicin should not exceed 550 mg / m 2.
In patients who have previously received radiation therapy in the lung and mediastinum, the total dose of doxorubicin should not exceed 400 mg / m 2.
For intravenous administration, dissolve the contents of the vial of doxorubicin (10 mg) in 5 ml of isotonic sodium chloride solution.
When doxorubicin is used, leukopenia and thrombocytopenia, stomatitis, nausea and vomiting (immediately after the drug administration), alopecia (reversible), allergic reactions, necrosis of the subcutaneous fatty tissue when the drug is injected under the skin, phlebitis are possible.
Doxorubicin should be used under strict hematological control.
One of the characteristic toxicological features of doxorubicin is its cardiotoxic effect.
In the course of drug treatment, cardiomyopathy, pain in the heart area, rhythm disturbances, heart failure, lowering blood pressure can develop. For severe cardiac arrhythmias or congestive insufficiency, doxorubicin treatment should be stopped immediately.
Doxorubicin is contraindicated for severe disorders of the liver and kidneys, leukopenia (below 3, 5 x 10 9 / l), thrombocytopenia (below 12 x 10 9 / l), severe concomitant heart diseases (myocarditis, myocardial infarction, significant arrhythmias), bleeding , tuberculosis, pregnancy, gastric ulcer and duodenal ulcer.